Abatacept, a medication used to treat rheumatoid arthritis, may also lower the risk of developing the disease in individuals who are already vulnerable. This finding comes from a study reported in a major medical journal. (Lancet)
Rheumatoid arthritis arises when the immune system mistakenly targets healthy joint tissues, leading to pain, swelling, and a compromised quality of life. While there is no cure, certain treatments can slow progression and improve function. Abatacept has emerged as one of the most effective options, and it is administered weekly either by injection or through an intravenous infusion. (Attribution: study data)
In the trial, researchers from King’s College London enrolled 213 adults with early signs of RA who had joint pain but no visible swelling. Half received a weekly placebo for one year, while the remainder received Abatacept. (Attribution: clinical trial)
After 12 months, fewer participants on Abatacept showed progression of arthritis symptoms compared with those on placebo: 6% versus 29%. At the 24‑month mark, 25% of the Abatacept group saw progression compared with 37% in the placebo group. (Data attributed to the trial results)
The treatment also lowered joint pain and inflammation, and ultrasound evaluations indicated reduced activity in the joint lining. Patients reported better mobility and an improved overall quality of life while on therapy. (Attribution: patient-reported outcomes)
Possible side effects of abatacept include upper respiratory infections, dizziness, nausea, and diarrhea. While these events are usually not life‑threatening, they can influence who might derive the greatest benefit from the medication and require careful monitoring by clinicians. (Attribution: safety data)
In clinical discussions, some patients and clinicians consider the trade‑offs between symptom control and potential adverse events when deciding on treatment. A physician might explore the risk profile and prior health history to determine suitability for abatacept as part of a broader RA management plan. (Attribution: expert opinion)
What could explain a sudden, intense swelling between the toes? It may involve several conditions outside of rheumatoid arthritis and should be evaluated by a healthcare professional. (Clinical guidance)